(Q53919527)

22 May 2018

title

The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients. (English)

1 reference

22 May 2018

1 reference

1 reference

Konstas AG

1

1 reference

22 May 2018

Maltezos A

2

1 reference

22 May 2018

Mantziris DA

3

1 reference

22 May 2018

Sine CS

4

1 reference

22 May 2018

Stewart WC

5

1 reference

22 May 2018

publication date

1 June 1999

1 reference

22 May 2018

published in

Eye

1 reference

22 May 2018

volume

13 ( Pt 3a)

1 reference

22 May 2018

page(s)

314-318

1 reference

22 May 2018

https://scigraph.springernature.com/pub.10.1038/eye.1999.81

exact match

0 references

cites work

Prevalence, diagnostic features, and response to trabeculectomy in exfoliation glaucoma.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1999.81

Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1999.81

Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1999.81

A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1999.81

The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1999.81

Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1999.81

Gonioscopic findings in Greek patients with exfoliation glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1999.81

Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1999.81

inferred from DOI database lookup

7 January 2021

based on heuristic

Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1999.81

inferred from DOI database lookup

7 January 2021

based on heuristic

Dynamics of aqueous humor in the syndrome of exfoliation with glaucoma.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.1999.81

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/EYE.1999.81

1 reference

22 May 2018

Dimensions Publication ID

1011331136

0 references

1 reference

22 May 2018